The Relative Strength (RS) Rating for Axsome Therapeutics entered a new percentile Friday, with an increase from 79 to 83.
Looking For The Best Stocks To Buy And Watch? Start Here
This exclusive rating from Investor's Business Daily measures share price movement with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners tend to have an 80 or higher RS Rating in the early stages of their moves.
Axsome Therapeutics is trying to complete a cup with handle with a 130.00 buy point. See if it can clear the breakout price in heavy volume. Be aware that it's a third-stage base. Such later-stage patterns involve more risk and are more and have a higher likelihood to fail than first- or second-stage consolidations.
The company posted 0% earnings growth in its most recent report. Revenue gains came in at 72%. The next quarterly numbers are expected on or around Nov. 3.
Axsome Therapeutics earns the No. 174 rank among its peers in the Medical-Biomed/Biotech industry group. Aurinia Pharmaceuticals, Incyte and argenx ADR are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
